Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development

被引:50
作者
Gonin, P
Gaillard, C
机构
[1] Genethon, CNRS, UMR 8115, F-91002 Evry, France
[2] GenoSafe SAS, Evry, France
关键词
quantitative PCR; biodistribution; gene transfer; toxicology; safety; gene vectors;
D O I
10.1038/sj.gt.3302378
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Techniques allowing for gene transfer vectors biodistribution investigation, in the frame of preclinical gene therapy development, are exposed. Emphasis is given on validation and test performance assessment. In the second part, specific gene vector distribution properties are reviewed (adenovirus, AAV, plasmid, retroviruses, herpes-derived vectors, germline transmission risks). The rationale for biodistribution by quantitative PCR, animal study and result interpretation is discussed. The importance and pivotal role of biodistribution study in gene transfer medicine development is shown through the determination of target organs for toxicity, germline transmission assessment and determination of risks of shedding and spreading of vectors in the gene transfer recipient and the environment.
引用
收藏
页码:S98 / S108
页数:11
相关论文
共 81 条
[1]   CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors [J].
Alemany, R ;
Curiel, DT .
GENE THERAPY, 2001, 8 (17) :1347-1353
[2]   Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males [J].
Arruda, VR ;
Fields, PA ;
Milner, R ;
Wainwright, L ;
De Miguel, MP ;
Donovan, PJ ;
Herzog, RW ;
Nichols, TC ;
Biegel, JA ;
Razavi, M ;
Dake, M ;
Huff, D ;
Flake, AW ;
Couto, L ;
Kay, MA ;
High, KA .
MOLECULAR THERAPY, 2001, 4 (06) :586-592
[3]  
Behrens A, 2002, INVEST OPHTH VIS SCI, V43, P968
[4]   Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial [J].
Bellon, G ;
MichelCalemard, L ;
Thouvenot, D ;
Jagneaux, V ;
Poitevin, F ;
Malcus, C ;
Accart, N ;
Layani, MP ;
Aymard, M ;
Bernon, H ;
Bienvenu, J ;
Courtney, M ;
Doring, G ;
Gilly, B ;
Gilly, R ;
Lamy, D ;
Levrey, H ;
Morel, Y ;
Paulin, C ;
Perraud, F ;
Rodillon, L ;
Sene, C ;
So, S ;
TouraineMoulin, F ;
Schatz, C ;
Pavirani, A .
HUMAN GENE THERAPY, 1997, 8 (01) :15-25
[5]   The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors [J].
Bernt, KM ;
Ni, SH ;
Li, ZY ;
Shayakhmetov, DM ;
Lieber, A .
MOLECULAR THERAPY, 2003, 8 (05) :746-755
[6]   DNA binding chelates for nonviral gene delivery imaging [J].
Bogdanov, A ;
Tung, CH ;
Bredow, S ;
Weissleder, R .
GENE THERAPY, 2001, 8 (07) :515-522
[7]   Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates [J].
Brunetti-Pierri, N ;
Palmer, DJ ;
Beaudet, AL ;
Carey, KD ;
Finegold, M ;
Ng, P .
HUMAN GENE THERAPY, 2004, 15 (01) :35-46
[8]   Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product [J].
Chan, JMK ;
Villarreal, G ;
Jin, WW ;
Stepan, T ;
Burstein, H ;
Wahl, SM .
MOLECULAR THERAPY, 2002, 6 (06) :727-736
[9]   Rate of biodistribution of STEALTH® liposomes to tumor and skin:: influence of liposome diameter and implications for toxicity and therapeutic activity [J].
Charrois, GJR ;
Allen, TM .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2003, 1609 (01) :102-108
[10]  
Cichon G, 1999, J GENE MED, V1, P360, DOI 10.1002/(SICI)1521-2254(199909/10)1:5<360::AID-JGM54>3.0.CO